Top Markets
Coin of the day
Petros Pharmaceuticals, Inc. Petros Pharmaceuticals, Inc.

Petros Pharmaceuticals, Inc.

PTPI
Rank in Stocks #40525
Petros Pharmaceuticals, Inc. is a pharmaceutical company dedicated to male... Petros Pharmaceuticals, Inc. is a pharmaceutical company dedicated to male health solutions. Their activities include both the commercialization and ongoing development of Stendra, a prescription PDE-5 inhibitor specifically designed for treating erectile dysfunction (ED). Furthermore, Petros is advancing H100, a proprietary topical formulation currently in development as a potential treatment for acute Peyronie's disease. The company's offerings also extend to a range of erectile dysfunction products, such as vacuum erection devices. Petros Pharmaceuticals, Inc. operates from its base in New York, New York.
Share Price
$0.0034
Market Cap
$144.07K
Change (1 day)
13.33%
Change (1 year)
-88.67%
Country
US
Trade Petros Pharmaceuticals, Inc. (PTPI)

Category

Revenue for Petros Pharmaceuticals, Inc. (PTPI)
Revenue in Aug 2026 TTM: 0
According to Petros Pharmaceuticals, Inc. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Petros Pharmaceuticals, Inc. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors